To include your compound in the COVID-19 Resource Center, submit it here.

D2E7 adalimumab: Phase III results; under review in the U.S. and Europe

In a double-blind Phase III (DE019) trial in 619 patients who did not completely respond to methotrexate, both D2E7 given 20 mg

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE